Tags

Type your tag names separated by a space and hit enter

Migraine: emerging treatment options for preventive and acute attack therapy.
Expert Opin Emerg Drugs 2006; 11(3):419-27EO

Abstract

This review discusses emerging treatments of migraine in the context of what is now available. At present, patients are treated with a range of acute attack medicines or preventive treatments, with many having significant drawbacks. Important unmet needs are acute attack treatments that act by exclusively neural mechanisms with no vascular effects, and effective, well tolerated preventive medicines. Calcitonin gene-related peptide receptor antagonist, vanilloid receptor antagonists and nitric oxide synthase inhibitors are all in clinical trials for acute migraine. Tonaberset (a gap-junction blocker), an inducible nitric oxide synthase inhibitor and botulinum toxin A are in clinical trials for preventive therapy. Device-based approaches using neurostimulation of the occipital nerve are being studied, although the first study of patent foramen ovale closure for migraine prevention failed.

Authors+Show Affiliations

Institute of Neurology, Headache Group, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK. peterg@ion.ucl.ac.uk

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16939382

Citation

Goadsby, Peter J.. "Migraine: Emerging Treatment Options for Preventive and Acute Attack Therapy." Expert Opinion On Emerging Drugs, vol. 11, no. 3, 2006, pp. 419-27.
Goadsby PJ. Migraine: emerging treatment options for preventive and acute attack therapy. Expert Opin Emerg Drugs. 2006;11(3):419-27.
Goadsby, P. J. (2006). Migraine: emerging treatment options for preventive and acute attack therapy. Expert Opinion On Emerging Drugs, 11(3), pp. 419-27.
Goadsby PJ. Migraine: Emerging Treatment Options for Preventive and Acute Attack Therapy. Expert Opin Emerg Drugs. 2006;11(3):419-27. PubMed PMID: 16939382.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Migraine: emerging treatment options for preventive and acute attack therapy. A1 - Goadsby,Peter J, PY - 2006/8/31/pubmed PY - 2006/9/26/medline PY - 2006/8/31/entrez SP - 419 EP - 27 JF - Expert opinion on emerging drugs JO - Expert Opin Emerg Drugs VL - 11 IS - 3 N2 - This review discusses emerging treatments of migraine in the context of what is now available. At present, patients are treated with a range of acute attack medicines or preventive treatments, with many having significant drawbacks. Important unmet needs are acute attack treatments that act by exclusively neural mechanisms with no vascular effects, and effective, well tolerated preventive medicines. Calcitonin gene-related peptide receptor antagonist, vanilloid receptor antagonists and nitric oxide synthase inhibitors are all in clinical trials for acute migraine. Tonaberset (a gap-junction blocker), an inducible nitric oxide synthase inhibitor and botulinum toxin A are in clinical trials for preventive therapy. Device-based approaches using neurostimulation of the occipital nerve are being studied, although the first study of patent foramen ovale closure for migraine prevention failed. SN - 1744-7623 UR - https://www.unboundmedicine.com/medline/citation/16939382/Migraine:_emerging_treatment_options_for_preventive_and_acute_attack_therapy_ L2 - http://www.tandfonline.com/doi/full/10.1517/14728214.11.3.419 DB - PRIME DP - Unbound Medicine ER -